223 related articles for article (PubMed ID: 31189116)
41. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Perez-Soler R; Glisson BS; Lee JS; Fossella FV; Murphy WK; Shin DM; Hong WK
J Clin Oncol; 1996 Oct; 14(10):2785-90. PubMed ID: 8874340
[TBL] [Abstract][Full Text] [Related]
42. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Johnson FM; Krug LM; Tran HT; Shoaf S; Prieto VG; Tamboli P; Peeples B; Patel J; Glisson BS
Cancer; 2006 Jan; 106(2):366-74. PubMed ID: 16342249
[TBL] [Abstract][Full Text] [Related]
43. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
44. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs.
Guohua H; Hongyang L; Zhiming J; Danhua Z; Haifang W
Biosens Bioelectron; 2017 Nov; 97():184-195. PubMed ID: 28599178
[TBL] [Abstract][Full Text] [Related]
45. [Phase II study of lung cancer--evaluation of new drug in small cell lung cancer (SCLC) and phase II testing of analogues].
Furuse K
Gan To Kagaku Ryoho; 1991 Jul; 18(9):1499-503. PubMed ID: 1649580
[TBL] [Abstract][Full Text] [Related]
46. Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
Yang X; Bai F; Xu Y; Chen Y; Chen L
Cell Physiol Biochem; 2017; 43(3):1126-1139. PubMed ID: 28977798
[TBL] [Abstract][Full Text] [Related]
47. SIRT3 increases cisplatin sensitivity of small-cell lung cancer through apoptosis.
Guo R; Li Y; Xue Y; Chen Y; Li J; Deng X; Su J; Liu Y; Sun L
Gene; 2020 Jun; 745():144629. PubMed ID: 32229158
[TBL] [Abstract][Full Text] [Related]
48. Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin.
Kaufmann SH; Kalemkerian GP; Jasti R; Mabry M
Biochem Pharmacol; 1995 Dec; 50(12):1987-93. PubMed ID: 8849324
[TBL] [Abstract][Full Text] [Related]
49. Exploring the mechanism of cisplatin resistance by transcriptome sequencing and reversing the chemoresistance by autophagy inhibition in small cell lung cancer.
Ma K; Li S; Huo X; Guo M; Du X; Li C; Liu X; Lv J; Chen Z
Biochem Biophys Res Commun; 2020 Dec; 533(3):474-480. PubMed ID: 32977950
[TBL] [Abstract][Full Text] [Related]
50. Cisplatin for small-cell lung cancer.
Aisner J; Abrams J
Semin Oncol; 1989 Aug; 16(4 Suppl 6):2-9. PubMed ID: 2548282
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
Kudoh S; Fujiwara Y; Takada Y; Yamamoto H; Kinoshita A; Ariyoshi Y; Furuse K; Fukuoka M
J Clin Oncol; 1998 Mar; 16(3):1068-74. PubMed ID: 9508192
[TBL] [Abstract][Full Text] [Related]
52. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.
Budak-Alpdogan T; Chen B; Warrier A; Medina DJ; Moore D; Bertino JR
Clin Cancer Res; 2009 Feb; 15(4):1232-40. PubMed ID: 19174488
[TBL] [Abstract][Full Text] [Related]
53. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.
Oliver TG; Mercer KL; Sayles LC; Burke JR; Mendus D; Lovejoy KS; Cheng MH; Subramanian A; Mu D; Powers S; Crowley D; Bronson RT; Whittaker CA; Bhutkar A; Lippard SJ; Golub T; Thomale J; Jacks T; Sweet-Cordero EA
Genes Dev; 2010 Apr; 24(8):837-52. PubMed ID: 20395368
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
55. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
56. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
[TBL] [Abstract][Full Text] [Related]
57. Identification of uPAR-positive chemoresistant cells in small cell lung cancer.
Gutova M; Najbauer J; Gevorgyan A; Metz MZ; Weng Y; Shih CC; Aboody KS
PLoS One; 2007 Feb; 2(2):e243. PubMed ID: 17327908
[TBL] [Abstract][Full Text] [Related]
58. Repression of linc01555 up-regulates angiomotin-p130 via the microRNA-122-5p/clic1 axis to impact vasculogenic mimicry-mediated chemotherapy resistance in small cell lung cancer.
Li D; Shen Y; Ren H; Wang L; Yang J; Wang Y
Cell Cycle; 2023 Jan; 22(2):255-268. PubMed ID: 36045598
[TBL] [Abstract][Full Text] [Related]
59. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract][Full Text] [Related]
60. [Modulation of human small cell lung cancer cell line GLC4/ADR multidrug resistance in the inhibition of multidrug resistance-associated protein and its antisense].
Peng X; Feng F; Zhang W
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):355-8. PubMed ID: 11810759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
